159 related articles for article (PubMed ID: 30144378)
1. ADP sensitizes ZL55 cells to the activity of cisplatin.
Muscella A; Cossa LG; Vetrugno C; Antonaci G; Marsigliante S
J Cell Physiol; 2019 Apr; 234(4):4409-4417. PubMed ID: 30144378
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ZL55 cell proliferation by ADP via PKC-dependent signalling pathway.
Muscella A; Cossa LG; Vetrugno C; Antonaci G; Marsigliante S
J Cell Physiol; 2018 Mar; 233(3):2526-2536. PubMed ID: 28777435
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma.
Hartman ML; Esposito JM; Yeap BY; Sugarbaker DJ
J Thorac Cardiovasc Surg; 2010 May; 139(5):1233-40. PubMed ID: 19853261
[TBL] [Abstract][Full Text] [Related]
4. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy.
Hoda MA; Mohamed A; Ghanim B; Filipits M; Hegedus B; Tamura M; Berta J; Kubista B; Dome B; Grusch M; Setinek U; Micksche M; Klepetko W; Berger W
J Thorac Oncol; 2011 May; 6(5):852-63. PubMed ID: 21358348
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells.
Hwang KE; Kim YS; Jung JW; Kwon SJ; Park DS; Cha BK; Oh SH; Yoon KH; Jeong ET; Kim HR
Oncotarget; 2015 Oct; 6(30):29482-96. PubMed ID: 26334320
[TBL] [Abstract][Full Text] [Related]
6. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
Zanellato I; Colangelo D; Osella D
Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors.
Echeverry N; Ziltener G; Barbone D; Weder W; Stahel RA; Broaddus VC; Felley-Bosco E
Cell Death Dis; 2015 May; 6(5):e1757. PubMed ID: 25950487
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis by [Pt(O,O'-acac)(γ-acac)(DMS)] requires PKC-δ mediated p53 activation in malignant pleural mesothelioma.
Muscella A; Vetrugno C; Cossa LG; Antonaci G; Barca A; De Pascali SA; Fanizzi FP; Marsigliante S
PLoS One; 2017; 12(7):e0181114. PubMed ID: 28704484
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma.
Vanbervliet-Defrance B; Delaunay T; Daunizeau T; Kepenekian V; Glehen O; Weber K; Estornes Y; Ziverec A; Djemal L; Delphin M; Lantuéjoul S; Passot G; Grégoire M; Micheau O; Blanquart C; Renno T; Fonteneau JF; Lebecque S; Mahtouk K
Cancer Lett; 2020 Mar; 472():29-39. PubMed ID: 31838086
[TBL] [Abstract][Full Text] [Related]
10. Pro-oxidant activity of sulforaphane and cisplatin potentiates apoptosis and simultaneously promotes autophagy in malignant mesothelioma cells.
Lee YJ; Lee SH
Mol Med Rep; 2017 Aug; 16(2):2133-2141. PubMed ID: 28627624
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma.
Moriya M; Yamada T; Tamura M; Ishikawa D; Hoda MA; Matsumoto I; Klepetko W; Oda M; Yano S; Watanabe G
Oncol Rep; 2014 Mar; 31(3):1109-15. PubMed ID: 24378576
[TBL] [Abstract][Full Text] [Related]
12. In Vitro and In Vivo Antitumor Activity of [Pt(O,O'-acac)(γ-acac)(DMS)] in Malignant Pleural Mesothelioma.
Muscella A; Vetrugno C; Cossa LG; Antonaci G; De Nuccio F; De Pascali SA; Fanizzi FP; Marsigliante S
PLoS One; 2016; 11(11):e0165154. PubMed ID: 27806086
[TBL] [Abstract][Full Text] [Related]
13. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
Kanteti R; Riehm JJ; Dhanasingh I; Lennon FE; Mirzapoiazova T; Mambetsariev B; Kindler HL; Salgia R
Sci Rep; 2016 Sep; 6():32992. PubMed ID: 27623107
[TBL] [Abstract][Full Text] [Related]
14. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.
Nagata Y; Takahashi A; Ohnishi K; Ota I; Ohnishi T; Tojo T; Taniguchi S
Int J Oncol; 2010 Oct; 37(4):1001-10. PubMed ID: 20811722
[TBL] [Abstract][Full Text] [Related]
15. Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.
Urso L; Cavallari I; Silic-Benussi M; Biasini L; Zago G; Calabrese F; Conte PF; Ciminale V; Pasello G
Oncotarget; 2017 Jul; 8(27):44232-44241. PubMed ID: 28562336
[TBL] [Abstract][Full Text] [Related]
16. Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed.
Li Q; Kawamura K; Yamanaka M; Okamoto S; Yang S; Yamauchi S; Fukamachi T; Kobayashi H; Tada Y; Takiguchi Y; Tatsumi K; Shimada H; Hiroshima K; Tagawa M
Cancer Gene Ther; 2012 Mar; 19(3):218-28. PubMed ID: 22223137
[TBL] [Abstract][Full Text] [Related]
17. Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways.
Shimazu K; Tada Y; Morinaga T; Shingyoji M; Sekine I; Shimada H; Hiroshima K; Namiki T; Tatsumi K; Tagawa M
BMC Cancer; 2017 May; 17(1):309. PubMed ID: 28464864
[TBL] [Abstract][Full Text] [Related]
18. mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids.
Wilson SM; Barbone D; Yang TM; Jablons DM; Bueno R; Sugarbaker DJ; Nishimura SL; Gordon GJ; Broaddus VC
Am J Respir Cell Mol Biol; 2008 Nov; 39(5):576-83. PubMed ID: 18511708
[TBL] [Abstract][Full Text] [Related]
19. Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells.
Tyler A; Johansson A; Karlsson T; Gudey SK; Brännström T; Grankvist K; Behnam-Motlagh P
Exp Cell Res; 2015 Aug; 336(1):23-32. PubMed ID: 26004871
[TBL] [Abstract][Full Text] [Related]
20. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
